Nathalie ter Wengel M.D. is the European Lead Worldwide Business Development at Pfizer, where she is responsible for establishing new collaborations and exploring global licensing and other corporate development opportunities across all therapeutic areas that Pfizer is interested in with European companies. Previous to this role, she was the European Head for External Science & Innovation at Pfizer.

Nathalie obtained her Doctor of Medicine degree at the Vrije Universiteit in Amsterdam. She has an international background and a broad knowledge in the medical field, having worked in the hospital with extensive experience in Internal Medicine. Nathalie started her commercial career as European Medical Manager at Pfizer, where she successfully led ambitious international projects, combining a business perspective with her medical knowledge. It was this experience, coupled with her father’s illness that convinced her of the urgent need for change in the pharmaceutical industry. Consequently, she started up a company called myTomorrows focused on compassionate use, where she served as Chief Medical Officer before joining Galapagos as Business Development Director, where she played a key role in the very successful NASDAQ IPO and in the partnering of filgotinib.